Stocks Health care GYRE
NASDAQ · Health careGyre Therapeutics, Inc. (GYRE)
Gyre Therapeutics, Inc. brought in $116.4M of revenue over the twelve months to June 30, 2026, up 10.7% from a year earlier. It posted a net loss of $25.7M. In fiscal 2025 capital spending exceeded operating cash flow by $180K. At June 30, 2026 it held $43.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
What Gyre Therapeutics, Inc. does
Gyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GYRE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $116.6M | $9.9M | $0.02 | -$180K |
| 2024 | $105.8M | $17.9M | $0.05 | -$6M |
| 2023 | $113.5M | -$85.5M | -$1.41 | $17.4M |
| 2022 | $102.3M | $4.3M | $0.03 | $5.7M |
| 2021 | $7.3M | -$87.9M | -$2.87 | -$84.6M |
| 2020 | $20.9M | -$56.2M | -$2.93 | n/a |
Latest SEC filings
What Gyre Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 1, 2026
- August 27, 2026
- August 26, 2026
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026
- August 7, 2026
- July 16, 2026
- July 15, 2026Quarterly results 8-K/A
- July 13, 2026
- June 23, 2026
- June 16, 2026
Questions about GYRE
What does Gyre Therapeutics, Inc. do?
Gyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GYRE.
Is Gyre Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $25.7M on revenue of $116.4M.
How much revenue does Gyre Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Gyre Therapeutics, Inc. reported revenue of $116.4M. That is 10.7% more than a year earlier.
When did Gyre Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 1, 2026.
Similar companies
Follow GYRE
Get an email when Gyre Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow GYRE: get an email when it filesWhere the numbers come from
Financial figures are the values Gyre Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.